Research.Patient.info

Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory research hub

1 indexed studies · 0 currently recruiting

authorisedHuman Pharmacology (Phase I)- First administration to humans
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
This study is testing a new medicine ([211At]At-Girentuximab) for bladder cancer that hasn't responded to usual treatments. It's the first time this medicine is being given to people, to check if it's safe and how well the body handles it. We're also looking for any early signs that it might help tackle the cancer.
France